Clinical trials: IrAE
Malignancy, Immune Related Adverse Events
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Immunotherapies have improved cancer outcomes, but have a unique profile of immune-related adverse events (irAEs). Biorepositories have been established to collect data and samples to help improve our understanding of irAEs…
- Trial name
- NCT06789601
- Testing
- Informatics system for eligibility monitoring, Standard eligibility monitoring
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Brigham and Women's Hospital
Cancer, Immune-related Adverse Event
EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBase®, the WHO's international database.
- Conditions
- Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- EXIT (NCT05934214)
- Testing
- Immune checkpoint inhibitor
- Where
- 2 sites in France
- Volunteers
- 141,630 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Immune-related Adverse Event
Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype
This study is an open, monocentric study. It includes patients with irAE refractory to standard therapy or patients where corticosteroids cannot be tapered.
- Trial name
- PRIA (NCT05700565)
- Testing
- Extracorporeal photopheresis, Other immunosuppressive or immunomodulatory drugs
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Lucie Heinzerling